Novo Nordisk launched a subscription program for Wegovy (semaglutide) starting March 31, 2026, offering tiered pricing to reduce costs for self-pay patients. Monthly prices range from $329 to $249 for injections (up to $1,200 annual savings) and $289 to $249 for oral versions through telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join later. The program aims to improve treatment adherence and address cost barriers.

LifeMD announced a quarterly cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on April 15, 2026, to shareholders of record as of April 3, 2026.

Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.

LifeMD, Inc. announced a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on January 15, 2026. The announcement reflects the company's financial stability as a leading virtual primary care provider.

Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.

LifeMD announced lower cash-pay pricing for Wegovy and Ozempic medications at $199 per month, supporting patients paying out of pocket through its Weight Management Program in collaboration with Novo Nordisk.

The global non-sterile compounding pharmacy market is projected to grow from $5.97 billion in 2024 to $12.11 billion by 2034, driven by increasing demand for personalized medications and growing chronic diseases, with North America currently leading the market.

The Schall Law Firm is pursuing a class action lawsuit against LifeMD for allegedly making false and misleading statements about its competitive position and financial guidance during May-August 2025.

Rosen Law Firm is investigating potential securities claims for Telix Pharmaceuticals shareholders after the company received an SEC subpoena related to prostate cancer therapeutic candidate disclosures, which caused a 10.44% stock price drop.

A class action lawsuit has been filed against LifeMD, alleging false statements about the company's competitive position and financial guidance for 2025, with potential securities law violations.

A class action lawsuit has been filed against LifeMD alleging false statements about the company's competitive position and financial guidance during May 7-August 5, 2025, with investors having until October 27th to apply as lead plaintiff.

Rosen Law Firm reminds LifeMD investors of an important October 27, 2025 deadline for a securities class action lawsuit, alleging the company made false or misleading statements about its competitive position and financial guidance.